All Press
Publications
All
2021
2020
2019
2018
2017
2016
All
2021
2020
2019
2015

May 17, 2021

Avidea Technologies and University of Maryland Awarded Grant to Evaluate Avidea’s SNAPvaxTM Tolerance Vaccine (TV) for Treating Autoimmune Diseases

March 25, 2021

Avidea to present at World Immunotherapy Congress on March 29th and NeoAg Summit on April 21st.

November 2, 2020

Avidea Technologies and Collaborators Publish Results in Nature Immunology Showing SNAPvaxTM Cancer Vaccine Administered IV Generates Stem-Like (TCF1+) Neoantigen-Sepcific CD8+ T cells Resulting in Improved Efficacy

Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells

March 9, 2020

Nature Biotechnology features Avidea’s self-assembling nanoparticle technology, SNAPvax (SNP-7/8a) on the Cover of its March 2020 issue

Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens

August 16, 2019

Avidea is accepted into the Nanoparticle Characterization Lab at the Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute

July 17, 2019

Avidea co-authors publication on combining therapeutic cancer vaccines with oncolytic virotherapy

Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance

June 17, 2019

June 15, 2019

Avidea co-authors publication on intravenously administered nanomedicines for enhanced cancer immunotherapy in Cancer Letters

Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines

January 4, 2019

Avidea co-authors publication on polymer-TLR-7/8 agonist compositions for inducing CD8 T cell responses in ACS journal Biomacromolecules

Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction

May 23, 2018

Darrell Irvine, MIT Professor of Materials Science and Engineering, writes that Avidea’s technology linking TLR agonists to polymers is a “promising approach” to vaccine development in Nature Materials.

Material aid for vaccines

March 28, 2018

Avidea co-founder profiled by Johns Hopkins Technology Ventures

February 23, 2017

The National Institute of Allergy and Infectious Diseases (NIAID) and Avidea Technologies (Avidea) have entered into an agreement to evaluate the therapeutic potential of Avidea’s polymer-based vaccine technology, “Immunotherapeutic Nanoscaffolds” (IMNs), including Star polymers and self-assembling nanoparticles based on amphiphilic polymers (SNAP), in preclinical animal models for cancer, infectious and inflammatory diseases.

November 16, 2016

Avidea obtains exclusive rights to the immunotherapeutics delivery technology PolyMAP from PsiOxus Therapeutics

May 20, 2021

Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies

Demonstrates potential of Avidea's vaccine platform technology for inducing glycan-reactive broadly neutralizing antibodies

November 2, 2020

Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells.

Immunological mechanisms for enhanced efficacy by intravenous vaccination

January 13, 2020

Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.

Description of SNAPvax as a platform for promoting T cell immunity

January 4, 2019

Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction

Scientific principles underlying polymer-TLR-7/8 agonist based therapies

October 26, 2015

In vivo characterization of the physicochemical properties of polymers-linked TLR agonists that enhance vaccine immunogenicity.

Scientific principles underlying technology platforms